Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

• Awaiting development
• Reference number: GID-TA11835
• Expected publication date: TBC